Market Overview

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Share:

HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22, 2020.

CONFERENCE DETAILS

Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 
Date: Tuesday, Sept. 22, 2020 
Time: 1:40-2:20 p.m. ET

Live webcasts of the presentation will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.

About Marker Therapeutics, Inc. 
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-virtual-oppenheimer-fall-healthcare-life-sciences--medtech-summit-301132782.html

SOURCE Marker Therapeutics, Inc.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com